Peptide Cycling Protocols: Do You Need to Take Breaks?

Is Peptide Cycling Necessary?

Peptide cycling protocols, such as 8 to 12 weeks on and 4 to 6 weeks off, were not tested in any study on this page. Short human trials found the growth hormone (GH) response held over 8 to 15 days of repeat doses. No study here compared taking breaks with not taking them.

GH secretagogues are compounds that push your body to release more of its own GH. IGF-1 is a hormone that rises when GH rises. This page checks cycling claims about these compounds against the trial data.

Does Skipping a Peptide Cycling Break Cause Tolerance?

Tolerance means the body responds less to the same dose over time. Scientists call it desensitisation.

Earlier studies had hinted that nonstop dosing of GH-releasing peptides can blunt the GH response. One team tested short, repeated doses instead. Seven older adults, aged 67 to 80, took hexarelin by nose three times a day for 8 days. Their GH response held, with a trend upward. Seven older women, aged 63 to 80, took it by mouth three times a day for 15 days. Their GH response did not change. The authors found these separate daily doses did not blunt the GH response (Ghigo 1996).

CJC-1295 was tested in healthy adults aged 21 to 61. The two trials lasted 28 and 49 days. After one shot, GH rose 2 to 10 fold for 6 days or more, depending on the dose. IGF-1 rose 1.5 to 3 fold for 9 to 11 days. After several doses, IGF-1 stayed above its starting level for up to 28 days. The authors saw signs the effect built up over doses (Teichman 2005). Neither trial ran past 49 days.

The longest trial here used MK-677, also called ibutamoren. It is a pill that copies ghrelin, a hunger hormone. In all, 65 healthy adults aged 60 to 81 took it or a dummy pill once a day. MK-677 raised GH and IGF-1 to the levels of healthy young adults. The main results came at one year, and two-year data agreed (Nass 2008). A 2004 review also said long-term MK-677 brought GH pulses and IGF-1 back to young-adult levels (Smith et al. 2004).

What Does Receptor Research Say About Peptide Cycling?

Many hormones act through receptors on the cell surface. A receptor is a switch that picks up a signal. These ones are called GPCRs.

A 2017 review says these switches tune down in two phases. The fast phase takes minutes. Proteins called beta-arrestins sit on the switch and block its signal. The slow phase takes hours to days. The cell pulls switches inside, breaks some down and makes less RNA for new ones (Rajagopal and Shenoy 2017).

Recovery undoes those steps. Switches go back to the surface, or the cell makes new ones. The same review says recovery is only partly understood. A second review shows that two drugs can tune down the same switch in different ways (Kelly 2007). Its main example is the receptor morphine acts on. The 2017 review gives no recovery time in weeks.

What Does a Peptide Cycling Chart Actually Show?

This table sets each cycling claim against the studies above.

Does Peptide Cycling Apply to BPC-157 and TB-500?

No study cited here has tested whether these two stop working with repeat use. FDA's 2026 review found only five human studies of BPC-157 (FDA BPC-157 review). Its review of TB-500 found no clinical studies or human exposure data by any route (FDA TB-500 review). TB-500 is a seven-amino-acid piece of a natural protein, thymosin beta-4. FDA says the two are not the same thing.

Our BPC-157 vs TB-500 comparison sets out what the rat and lab studies found. The BPC-157 dosage page lists the doses used in published studies.

Is There a MOTS-c Peptide Cycling Protocol?

No tested one exists. MOTS-c is a small peptide coded in the DNA of mitochondria, the cell's power units. FDA's 2026 review found no published studies of MOTS-c products used in people and no human exposure data (FDA MOTS-c review). So no on and off plan has been measured in people. Our MOTS-c complete guide covers the mouse and cell work.

What Can Peptide Cycling Studies Not Tell You?

The studies are small. Each hexarelin group had seven people. The CJC-1295 trials lasted weeks. No study on this page tested ipamorelin or tesamorelin for tolerance.

Long-term use had measured effects. In the two-year MK-677 trial, fasting blood sugar rose. The body also used insulin less well. Cortisol, a stress hormone, rose too. The CJC-1295 trials reported no serious side effects.

Product quality is a separate question from cycling. Our recommended sources page covers suppliers. Our peptide stacks that work guide grades five stacks on the evidence. The CJC-1295 complete guide covers its trial doses and safety. The CJC-1295 side effects and safety page covers water retention, tingling and blood sugar.

Our piece on peptide dosing advice examines common dosage charts. Our insulin syringe units peptide dosing chart converts micrograms into units.

This content is for educational purposes only. These compounds are intended for research use. Nothing here replaces a conversation with a qualified clinician before you start, adjust or extend any protocol.